



Regular Meeting of the

Santa Clara County Health Authority Pharmacy & Therapeutics Committee

Thursday, April 30, 2020, 6:00 PM – 8:00 PM

Santa Clara Family Health Plan

6201 San Ignacio Ave, San Jose, CA 95119

Minutes (Open)

Members Present

Jimmy Lin, MD, Chair
Ali Alkoraishi, MD
Xuan Cung, PharmD
Dolly Goel, MD
Dang Huynh, PharmD, Director of Pharmacy
Laurie Nakahira, D.O., Chief Medical Officer
Peter Nguyen, D.O.
Jesse Parashar-Rokicki, MD

Members Absent

Amara Balakrishnan, MD
Hao Bui, BS, RPh
Narinder Singh, PharmD
Minh Thai, MD

Staff Present

Duyen Nguyen, PharmD, Clinical Pharmacist
Tami Otomo, PharmD, Clinical Pharmacist
Nancy Aguirre, Administrative Assistant

Others Present

Amy McCarty, PharmD, Clinical Program
Manager, MedImpact
Patti Connery, RPh, Account Executive,
MedImpact
Jessica Wong, PharmD, VMC Pharmacy
Resident

1. Roll Call

Jimmy Lin, MD, Chair, called the meeting to order at 6:09 pm. Roll call was taken and a quorum was not established.

2. Public Comment

There were no public comments.

3. Open Meeting Minutes

Review of the 4Q2019 Pharmacy & Therapeutics Committee (P&T) open meeting minutes was deferred until a quorum was established.

4. Standing Agenda Items

a. Chief Medical Officer Health Plan Updates

Laurie Nakahira, D.O., Chief Medical Officer (CMO), Santa Clara Family Health Plan (SCFHP), announced that Neal Jarecki, formerly the Controller at SCFHP, is now the Chief Financial Officer (CFO), as Dave Cameron retired. Also, Teresa Chapman joined SCFHP as the new Vice President of Human Resources, as Sharon Valdez retired.

During the current state of emergency due to coronavirus disease 2019 (COVID-19), roughly 96% of SCFHP's in-house staff are now working from home. SCFHP suspended prior authorizations (PA), with the exception of elective surgeries and procedures (effective 5/1/2020). Prescriptions are allowed to be filled for a 90-day supply. Some disinfectants and gloves were added to formulary with quantity limit restrictions.

A new telehealth capability for SCFHP's nurse advice line was recently implemented. Approximately 85 members have utilized this telehealth feature.

b. Plan/Global Medi-Cal Drug Use Review (DUR)

Tami Otomo, PharmD, SCFHP, announced that the due date for the annual Centers for Medicare and Medicaid Services (CMS) Managed Care Organization DUR Report has been extended to the end of September 2020 due to COVID-19.

c. Appeals & Grievance 4Q2019 Report

Dang Huynh, PharmD, Director of Pharmacy, SCFHP, presented the Appeals and Grievance 4Q219 Report. The Appeals & Grievance department is currently working on providing more detail on the types of cases handled by their team. Once completed, this analysis will be presented at an upcoming P&T Committee meeting.

d. Annual Pharmacy Policy Review

Dr. Huynh presented all of the pharmacy policies for annual review by the P&T Committee. He reported that the only policy with revisions was policy PH.10 Cal MediConnect Part D Transition (2020). Every year, the language in this policy is updated per CMS guidance and regulations. This policy was submitted and approved by CMS for calendar year 2020.

Motion to approve the policies was deferred until a quorum was established.

Adjourned to Closed Session at 6:44 p.m.

Pursuant to Welfare and Institutions Code Section 14087.36 (w)

5. Closed Meeting Minutes

6. Metrics and Financial Updates

a. Membership Report

b. Pharmacy Dashboard

Dolly Goel, MD, and Ali Alkoraishi, MD joined at 6:33 p.m. A quorum was established at this time.

c. Drug Use Evaluation

d. Drug Utilization & Spend

7. Discussion and Recommendations for Changes to SCFHP's Cal MediConnect Formulary & Coverage Determination Criteria

a. Pharmacy Benefit Manager 4Q2019 P&T Minutes

b. Pharmacy Benefit Manager 1Q2020 P&T Part D Actions

8. Discussion and Recommendations for Changes to SCFHP's Medi-Cal & Prior Authorization Criteria

a. Old Business/Follow-Up

- i. Statin Adherence**
- ii. Diabetes Type I & Type II**

b. Formulary Modifications

c. Fee-for-Service Contract Drug List Comparability

d. Prior Authorization Criteria

i. New or Revised Criteria

- 1. Deferasirox - *new*
- 2. Droximel fumarate - *new*
- 3. Fingolimod – *revised*;
- 4. Reauthorization-Opioids – *revised*;
- 5. Glatiramer acetate – *revised*;
- 6. Oxycodone extended-release – *revised*;
- 7. Tacrolimus ointment – *revised*;

ii. Annual Review

- 1. Ambrisentan – *no changes*
- 2. General Utilization Management – *no changes*
- 3. Milnacipran – *no changes*
- 4. Raloxifene – *no changes*

9. New Drugs and Class Reviews

a. Informational Only

- i. Multiple sclerosis – Ozanimod
- ii. Migraine Update – Eptinezumab
- iii. Hyperlipidemia – Nexletol, Nexlizet
- iv. Acute Hepatic Porphyria – Givlaari
- v. Epilepsy – Xcopri
- vi. Ulcerative Colitis Update
- vii. Sickle Cell Anemia Update
- viii. Oncology Update
- ix. Cystic Fibrosis Update
- x. Biosimilars Update
- xi. Autoimmune Updates
- xii. New Derivatives/formulations/combinations
- xiii. New and Expanded Label



Reconvened in Open Session at 7:15 p.m.


10. Discussion Items

a. New and Generic Pipeline

Dr. Huynh reviewed the New and Generic Pipeline and noted that Restasis has been on the generic pipeline for a long time with no release date.

11. Adjournment

The next P&T Committee meeting will be on June 18, 2020. The meeting was adjourned at 7:21 p.m.

DocuSigned by:

FD04B1D8F3CB407...
Jimmy Lin, MD, Chair

12/30/2020
Date